BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery [0.03%]
BRCA1和BRCA2相关的乳腺癌以及当前建模系统在药物发现中的作用
Oliver Trusler,Jacob Goodwin,Andrew L Laslett
Oliver Trusler
For a drug candidate to be fully developed takes years and investment of hundreds of millions of dollars. There is no doubt that drug development is difficult and risky, but vital to protecting against devastating disease. This difficulty i...
Power of two: combination of therapeutic approaches involving glucose transporter (GLUT) inhibitors to combat cancer [0.03%]
两种力量的结合：利用葡萄糖转运体(GLUT)抑制剂进行抗癌治疗的方法
Kalpana Tilekar,Neha Upadhyay,Cristina V Iancu et al.
Kalpana Tilekar et al.
Cancer research of the Warburg effect, a hallmark metabolic alteration in tumors, focused attention on glucose metabolism whose targeting uncovered several agents with promising anticancer effects at the preclinical level. These agents' mon...
Technologies for targeting DNA methylation modifications: Basic mechanism and potential application in cancer [0.03%]
靶向DNA甲基化修饰的技术：基本机制及其在癌症中的潜在应用
Jie Wang,Jing Yang,Dandan Li et al.
Jie Wang et al.
DNA methylation abnormalities are regarded as critical event for cancer initiation and development. Tumor-associated genes encompassing aberrant DNA methylation alterations at specific locus are correlated with chromatin remodeling and dysr...
The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation [0.03%]
PP2A亚基PR130是细胞发育和致癌转化的关键调节器
Melanie Dzulko,Miriam Pons,Andreas Henke et al.
Melanie Dzulko et al.
Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase. This enzyme is involved in a plethora of cellular processes, including apoptosis, autophagy, cell proliferation, and DNA repair. Remarkably, PP2A can act as a context-de...
David F Steiner,Po-Hsuan Cameron Chen,Craig H Mermel
David F Steiner
Recent advances in artificial intelligence show tremendous promise to improve the accuracy, reproducibility, and availability of medical diagnostics across a number of medical subspecialities. This is especially true in the field of digital...
The use of minimally invasive biomarkers for the diagnosis and prognosis of hepatocellular carcinoma [0.03%]
最小侵入性生物标志物在肝细胞癌的诊断和预后中的应用
Lucas Trevisan França de Lima,Daniel Broszczak,Xi Zhang et al.
Lucas Trevisan França de Lima et al.
Hepatocellular carcinoma (HCC) is a common cause of cancer-related deaths worldwide. Despite advances in systemic therapies, patient survival remains low due to late diagnosis and frequent underlying liver diseases. HCC diagnosis generally ...
Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy [0.03%]
妇科癌症的血管生成及抗血管生成治疗的选择
Bahar Yetkin-Arik,Arnoud W Kastelein,Ingeborg Klaassen et al.
Bahar Yetkin-Arik et al.
Angiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development of anti-angiogenesis therapy in gynecological cancers and improvement of its efficacy have been a ma...
Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis [0.03%]
非典型NF-κB途径在肿瘤发生中的药理学意义
Dhakshayini Morgan,Manoj Garg,Vinay Tergaonkar et al.
Dhakshayini Morgan et al.
The understanding of the impact of the non-canonical NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway in several human diseases including autoimmune, inflammatory and cancers has been on the rise. This pathway...
HOX genes and the NF-κB pathway: A convergence of developmental biology, inflammation and cancer biology [0.03%]
HOX基因和NF-κB通路：发育生物学、炎症和癌症生物学的汇聚点
Priya Pai,Saraswati Sukumar
Priya Pai
The roles of HOX transcription factors as oncogenes and tumor suppressor genes, and the NF-KB pathway in chronic inflammation, both leading to cancer are well-established. HOX transcription factors are members of an evolutionarily conserved...
New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab [0.03%]
针对HER2治疗的亲和蛋白的新见解：超越曲妥珠单抗
Vajihe Akbari,C Perry Chou,Daryoush Abedi
Vajihe Akbari
Human epidermal growth factor receptor 2 (HER2) is known as a potential target for both cancer treatment and diagnosis. One of the most interesting HER2-targeted therapeutics is an affinity protein which selectively recognizes and binds to ...